PET in neuro-oncology

被引:19
作者
Roelcke, U [1 ]
Leenders, KL
机构
[1] Paul Scherrer Inst, PET Program, CH-5232 Villigen, Switzerland
[2] Cantonal Hosp, Dept Neurol, CH-5001 Aarau, Switzerland
关键词
positron emission tomography; brain tumor; metabolism; proliferation; therapy response;
D O I
10.1007/s004320000158
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
This article reviews possible clinical applications of positron emission tomography (PET) in brain tumor patients. PET allows quantitative assessment of brain tumor pathophysiology and biochemistry. It therefore provides different information about tumors when compared to histological or neuroradiological methods. Common clinical indications for PET comprise ise tumor delineation and identification of the metabolically most active tumor regions (target for biopsy, differentiation of viable tumor from necrosis). Further. the spatial relation between brain activated e.g.. by speech, and the tumor bulk can be explored by activation studies. PET could also aid in the prediction of treatment response by measurement of tumor perfusion or hypoxia. Moreover, PET tracers could identify treatment targets e.g., gene products. The latter topic has not been systematically evaluated in human patients.
引用
收藏
页码:2 / 8
页数:7
相关论文
共 50 条
[1]   DISCREPANCIES IN BRAIN-TUMOR EXTENT AS SHOWN BY COMPUTED-TOMOGRAPHY AND POSITRON EMISSION TOMOGRAPHY USING [GA-68] EDTA, [C-11] GLUCOSE, AND [C-11] METHIONINE [J].
BERGSTROM, M ;
COLLINS, VP ;
EHRIN, E ;
ERICSON, K ;
ERIKSSON, L ;
GREITZ, T ;
HALLDIN, C ;
VONHOLST, H ;
LANGSTROM, B ;
LILJA, A ;
LUNDQVIST, H ;
NAGREN, K .
JOURNAL OF COMPUTER ASSISTED TOMOGRAPHY, 1983, 7 (06) :1062-1066
[2]   PET STUDY OF METHIONINE ACCUMULATION IN GLIOMA AND NORMAL BRAIN-TISSUE - COMPETITION WITH BRANCHED-CHAIN AMINO-ACIDS [J].
BERGSTROM, M ;
ERICSON, K ;
HAGENFELDT, L ;
MOSSKIN, M ;
VONHOLST, H ;
NOREN, G ;
ERIKSSON, L ;
EHRIN, E ;
JOHNSTROM, P .
JOURNAL OF COMPUTER ASSISTED TOMOGRAPHY, 1987, 11 (02) :208-213
[3]  
Blasberg RG, 2000, CANCER RES, V60, P624
[4]  
DEWITTE O, 1994, CANCER, V74, P2836, DOI 10.1002/1097-0142(19941115)74:10<2836::AID-CNCR2820741015>3.0.CO
[5]  
2-M
[6]  
Eary JF, 1999, CANCER RES, V59, P615
[7]  
FRANCAVILLA TL, 1989, NEUROSURGERY, V24, P1
[8]   A mutant herpes simplex virus type 1 thymidine kinase reporter gene shows improved sensitivity for imaging reporter gene expression with positron emission tomography [J].
Gambhir, SS ;
Bauer, E ;
Black, ME ;
Liang, QW ;
Kokoris, MS ;
Barrio, JR ;
Iyer, M ;
Namavari, M ;
Phelps, ME ;
Herschman, HR .
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA, 2000, 97 (06) :2785-2790
[9]  
Gambhir SS, 1998, J NUCL MED, V39, P2003
[10]   IDENTIFICATION OF EARLY RECURRENCE OF PRIMARY CENTRAL-NERVOUS-SYSTEM TUMORS BY [F-18] FLUORODEOXYGLUCOSE POSITRON EMISSION TOMOGRAPHY [J].
GLANTZ, MJ ;
HOFFMAN, JM ;
COLEMAN, RE ;
FRIEDMAN, AH ;
HANSON, MW ;
BURGER, PC ;
HERNDON, JE ;
MEISLER, WJ ;
SCHOLD, SC .
ANNALS OF NEUROLOGY, 1991, 29 (04) :347-355